Semaglutide for weight loss in advanced interstitial lung disease: A Pilot Study
Administratively Closed
18 years - 99 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD.
Detailed description of study
Semaglutide is a antidiabetic medication that has been known to help with long-term weight-loss management. The aim is to see the tolerability of the medication in patients with ILDs to promote weight-loss for feasibility of further pulmonary treatment. This is a 22-week study, during which you will be asked to work with the research study team and meet with them to complete research procedures.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research,Interstitial Lung Disease,Obesity
-
Age: 18 years - 99 years
-
Gender: All
- Diagnosis of an Interstitial Lung Disease
- BMI
> 35 kg/m2
- Requires
supplemental oxygen on exertion
- Semaglutide
prescribed by primary pulmonologist
- Insurance
approval
Updated on
05 Dec 2024.
Study ID: 851742
